ALS therapy: Targets for the future

Neurology

Volumn 47, Issue 6 SUPPL. 4, 1996, Pages

  Hugon, Jacques ^a  

^a School of Medicine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CILIARY NEUROTROPHIC FACTOR; ELIPRODIL; EXCITOTOXIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTROPHIC FACTOR; RILUZOLE; SCAVENGER; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; CEREBROSPINAL FLUID; CLINICAL TRIAL; DRUG TARGETING; GENE MUTATION; GENE TRANSFER; HUMAN; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NEUROFILAMENT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029730658     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_4.251s     Document Type: Review

References (42)

1. Brady S. Interfering with the runners. Nature 1995;375:12-13.
2. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
3. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-1468.
4. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
5. Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4:209-216.
6. Couratier P, Hugon J, Sindou P, et al. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 1993;341:265-268.
7. Couratier P, Sindou P, Esclaire F, et al. Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994;5: 1012-1014.
8. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
9. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu,Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;363:59-62.
10. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
11. Glenn Smith R, Alexianu ME, Crawford G, et al. Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc Natl Acad Sci USA 1994;91:3393-3397.
12. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994;3: 1757-1761.
13. Coté F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993;73:35-46.
14. Collard JF, Coté F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995;375:61-64.
15. Hugon J, Vallat JM. Abnormal distribution of phosphorylated neurofilaments in neuronal degeneration induced by kainic acid. Neurosci Lett 1990;119:45-48.
16. Nagaraja TN, Gourie-Devi M, Nalini A, et al. Neurofilament phosphorylation is enhanced in cultured chick spinal cord neurons exposed to cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neuropathol (Berl) 1994;88:349-352.
17. Hugon J. Excitotoxin blocking strategies in ALS. In: Serratrice G, Munsat Th, ed. Pathogenesis and therapy of ALS. Adv Neurol 1995;68:245-252.
18. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995;65:643-651.
19. Koh J, Palmer E, Cotman C. Activation of metabotropic glutamate receptor attenuates N-methyl-D-aspartate neurotoxicity in cortical cultures. Proc Natl Acad Sci USA 1992;88:9431-9435.
20. Bergeron C. Oxidative stress: its role in the pathogenesis of amyotrophic lateral sclerosis. J Neurol Sci 1995;129(suppl): 81-84.
21. Zeman S, Lloyd C, Meldrum B, et al. Excitatory amino acids, free radicals and the pathogenesis of motor neuron disease. Neuropathol Appl Neurobiol 1994;20:219-231.
22. Lafon-Cazal M, Pietri S, Culcasi M, et al. NMDA-dependent superoxide production and neurotoxicity. Nature 1993;364: 535-537.
23. Volterra A, Trotti D, Tromba C, et al. Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J Neurosci 1994;14:2924-2932.
24. Louwerse ES, Weverling GJ, Bossuyt PMM, et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559-564.
25. Choi DW, Hartley DM. Calcium and glutamate-induced cortical neuronal death. In: Waxmanm SG, ed. Molecular and cellular approaches to the treatment of neurological disease. New York: Raven Press, 1993:23-34.
26. Weiss JH, Hartley DH, Koh J, et al. Nifedipine attenuates slow excitatory amino acid neurotoxicity. Science 1990;247: 1474-1477.
27. Snider WD. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 1994;77:627-638.
28. Brown RH. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 1995;80:687-692.
29. Wolff JA. Postnatal gene transfer into the central nervous system. Curr Opin Neurobiol 1993;3:743-748.
30. Sahenk Z, Seharaseyon J, Mendell RJ, et al. Gene delivery to spinal motor neurons. Brain Res 1993;606:126-129.
31. McConkey DJ, Orrenius S. Signal transduction pathways to apoptosis. Trends Cell Biol 1994;4:370-375.
32. Migheli A, Cavalla P, Marino S, et al. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labelling of DNA strands breaks. J Neuropathol Exp Neurol 1994;53:606-616.
33. Yoshiyama Y, Yamada T, Asanuma K, et al. Apoptosis related antigen. Le Y and nick-end labelling are positive in spinal motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1994;88:207-211.
34. Troost D, Aten J, Morsink F, et al. Apoptosis in ALS is not restricted to motoneurons: Bcl-2 expression is increased in post-central cortex, adjacent to the affected motor cortex. J Neurol Sci 1995;129:79-80.
35. Roy N, Mahadevan MS, McLean M, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995;80:167-178.
36. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-165.
37. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995;375:78-81.
38. Garcia I, Martinou I, Tsujimoto Y, et al. Prevention of programmed cell death of sympathetic neurons by the bcl-2 protooncogene. Science 1992;258:302-304.
39. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
40. Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/ superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995;92:7162-7166.
41. Mitsumoto H, Ikeda K, Klinkosz B, et al. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994;265:1107-1110.
42. Sagot Y, Tan S, Baegte E, et al. Polymer encapsulated cell lines secreting neurotrophic factors can rescue motoneurons in an animal model of motoneuron disease. Soc Neurosci Abstr 1994;41(87.7).